Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus fludarabine/cytarabine/gemtuzumab ozogamicin versus fludarabine/cytarabine/gemtuzumab ozogamicin in children with relapsed AML
jRCT2031240283Phase 3Active, not recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of venetoclax, fludarabine, cytarabine, gemtuzumab ozogamicin and azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Overall Survival. Started Feb 2025; status: active, not recruiting.
02
Drugs
venetoclaxfludarabinecytarabinegemtuzumab ozogamicinazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2031240283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240283.